BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 17851558)

  • 1. FLT3 regulates beta-catenin tyrosine phosphorylation, nuclear localization, and transcriptional activity in acute myeloid leukemia cells.
    Kajiguchi T; Chung EJ; Lee S; Stine A; Kiyoi H; Naoe T; Levis MJ; Neckers L; Trepel JB
    Leukemia; 2007 Dec; 21(12):2476-84. PubMed ID: 17851558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Y654 of β-catenin is essential for FLT3/ITD-related tyrosine phosphorylation and nuclear localization of β-catenin.
    Kajiguchi T; Katsumi A; Tanizaki R; Kiyoi H; Naoe T
    Eur J Haematol; 2012 Apr; 88(4):314-20. PubMed ID: 22126602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD.
    Okamoto M; Hayakawa F; Miyata Y; Watamoto K; Emi N; Abe A; Kiyoi H; Towatari M; Naoe T
    Leukemia; 2007 Mar; 21(3):403-10. PubMed ID: 17230226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor.
    Grundler R; Thiede C; Miething C; Steudel C; Peschel C; Duyster J
    Blood; 2003 Jul; 102(2):646-51. PubMed ID: 12663439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leukemogenic potency of the novel FLT3-N676K mutant.
    Huang K; Yang M; Pan Z; Heidel FH; Scherr M; Eder M; Fischer T; Büsche G; Welte K; von Neuhoff N; Ganser A; Li Z
    Ann Hematol; 2016 Apr; 95(5):783-91. PubMed ID: 26891877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FYN expression potentiates FLT3-ITD induced STAT5 signaling in acute myeloid leukemia.
    Chougule RA; Kazi JU; Rönnstrand L
    Oncotarget; 2016 Mar; 7(9):9964-74. PubMed ID: 26848862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation.
    Brandts CH; Sargin B; Rode M; Biermann C; Lindtner B; Schwäble J; Buerger H; Müller-Tidow C; Choudhary C; McMahon M; Berdel WE; Serve H
    Cancer Res; 2005 Nov; 65(21):9643-50. PubMed ID: 16266983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations.
    Choudhary C; Schwäble J; Brandts C; Tickenbrock L; Sargin B; Kindler T; Fischer T; Berdel WE; Müller-Tidow C; Serve H
    Blood; 2005 Jul; 106(1):265-73. PubMed ID: 15769897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412.
    Seedhouse CH; Hunter HM; Lloyd-Lewis B; Massip AM; Pallis M; Carter GI; Grundy M; Shang S; Russell NH
    Leukemia; 2006 Dec; 20(12):2130-6. PubMed ID: 17066094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrin alphavbeta3 enhances β-catenin signaling in acute myeloid leukemia harboring Fms-like tyrosine kinase-3 internal tandem duplication mutations: implications for microenvironment influence on sorafenib sensitivity.
    Yi H; Zeng D; Shen Z; Liao J; Wang X; Liu Y; Zhang X; Kong P
    Oncotarget; 2016 Jun; 7(26):40387-40397. PubMed ID: 27248172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FLT3 mutations in acute myeloid leukemia cell lines.
    Quentmeier H; Reinhardt J; Zaborski M; Drexler HG
    Leukemia; 2003 Jan; 17(1):120-4. PubMed ID: 12529668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activity of sorafenib in FLT3-driven leukemic cells.
    Auclair D; Miller D; Yatsula V; Pickett W; Carter C; Chang Y; Zhang X; Wilkie D; Burd A; Shi H; Rocks S; Gedrich R; Abriola L; Vasavada H; Lynch M; Dumas J; Trail PA; Wilhelm SM
    Leukemia; 2007 Mar; 21(3):439-45. PubMed ID: 17205056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells.
    Stölzel F; Steudel C; Oelschlägel U; Mohr B; Koch S; Ehninger G; Thiede C
    Ann Hematol; 2010 Jul; 89(7):653-62. PubMed ID: 20119833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations.
    Mizuki M; Schwable J; Steur C; Choudhary C; Agrawal S; Sargin B; Steffen B; Matsumura I; Kanakura Y; Böhmer FD; Müller-Tidow C; Berdel WE; Serve H
    Blood; 2003 Apr; 101(8):3164-73. PubMed ID: 12468433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphoproteome analyses reveal specific implications of Hcls1, p21-activated kinase 1 and Ezrin in proliferation of a myeloid progenitor cell line downstream of wild-type and ITD mutant Fms-like tyrosine kinase 3 receptors.
    Habif G; Grasset MF; Kieffer-Jaquinod S; Kuhn L; Mouchiroud G; Gobert-Gosse S
    J Proteomics; 2013 Jan; 78():231-44. PubMed ID: 23017497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RGS2 is an important target gene of Flt3-ITD mutations in AML and functions in myeloid differentiation and leukemic transformation.
    Schwäble J; Choudhary C; Thiede C; Tickenbrock L; Sargin B; Steur C; Rehage M; Rudat A; Brandts C; Berdel WE; Müller-Tidow C; Serve H
    Blood; 2005 Mar; 105(5):2107-14. PubMed ID: 15536149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells.
    Bagrintseva K; Schwab R; Kohl TM; Schnittger S; Eichenlaub S; Ellwart JW; Hiddemann W; Spiekermann K
    Blood; 2004 Mar; 103(6):2266-75. PubMed ID: 14604974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autotaxin is expressed in FLT3-ITD positive acute myeloid leukemia and hematopoietic stem cells and promotes cell migration and proliferation.
    Ortlepp C; Steudel C; Heiderich C; Koch S; Jacobi A; Ryser M; Brenner S; Bornhäuser M; Brors B; Hofmann WK; Ehninger G; Thiede C
    Exp Hematol; 2013 May; 41(5):444-461.e4. PubMed ID: 23377000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BH3-only protein Bim more critical than Puma in tyrosine kinase inhibitor-induced apoptosis of human leukemic cells and transduced hematopoietic progenitors carrying oncogenic FLT3.
    Nordigården A; Kraft M; Eliasson P; Labi V; Lam EW; Villunger A; Jönsson JI
    Blood; 2009 Mar; 113(10):2302-11. PubMed ID: 19064725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of Wnt signaling in cKit-ITD mediated transformation and imatinib sensitivity in acute myeloid leukemia.
    Tickenbrock L; Hehn S; Sargin B; Evers G; Ng PR; Choudhary C; Berdel WE; Müller-Tidow C; Serve H
    Int J Hematol; 2008 Sep; 88(2):174-180. PubMed ID: 18668305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.